Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Dow
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,789,379

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,789,379 protect, and when does it expire?

Patent 5,789,379 protects GATTEX KIT and is included in one NDA.

Protection for GATTEX KIT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-six patent family members in seventeen countries.

Summary for Patent: 5,789,379
Title: Glucagon-like peptide-2 analogs
Abstract:Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J. (Toronto, CA), Crivici; Anna E. (Toronto, CA), Sumner-Smith; Martin (Bolton, CA)
Assignee: Allelix Biopharmaceutical Inc. (Mississauga, CA) 1149336 Ontario Inc. (Toronto, CA)
Application Number:08/669,791
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,789,379

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Nps Pharms Inc GATTEX KIT teduglutide recombinant POWDER;SUBCUTANEOUS 203441-001 Dec 21, 2012 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 5,789,379

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 227309   Start Trial
Austria 445641   Start Trial
Austria 478892   Start Trial
Australia 2500297   Start Trial
Australia 5265896   Start Trial
Australia 720493   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Merck
Moodys
Express Scripts
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.